Inhibition of respiratory syncytial virus by RhoA-derived peptides: Implications for the development of improved antiviral agents targeting heparin-binding viruses

Journal of Antimicrobial Chemotherapy

Volumn 54, Issue 2, 2004, Pages 299-302

  Budge, Philip J ^a,b   Graham, Barney S ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral agents; Dextran sulphate; Fusion inhibition; Heparan sulphate; Heparin; HIV; Human immunodeficiency virus; Polyanions; Post attachment neutralization; RSV; Sulphated polysaccharides

Indexed keywords

ANTIVIRUS AGENT; CD4 ANTIGEN; GLYCOPROTEIN GP 120; GLYCOSAMINOGLYCAN POLYSULFATE; HEPARIN; HYBRID PROTEIN; RESPIRATORY SYNCYTIAL VIRUS VACCINE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; VIRUS GLYCOPROTEIN;

ANTIVIRAL ACTIVITY; ARTICLE; COMPETITIVE INHIBITION; DRUG DESIGN; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; ENZYME LOCALIZATION; NONHUMAN; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RNA VIRUS INFECTION; VIRUS ENVELOPE; VIRUS INHIBITION; VIRUS REPLICATION;

ANTIGENS, CD4; ANTIVIRAL AGENTS; HEPARIN; HUMANS; PEPTIDES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RHOA GTP-BINDING PROTEIN;

EID: 4444239428     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dkh355     Document Type: Article

References (38)

1. Collins, P. L., Chanock, R. M. & Murphy, B. R. (2001). Respiratory syncytial virus. In Fields Virology, 4th edn (Knipe, D. M., Ed.), pp. 1443-85. Lippincott Williams and Wilkins, Philadelphia, PA, USA.
2. Thompson, W. W., Shay, D. K., Weintraub, E. et al. (2003). Mortality associated with influenza and respiratory syncytial virus in the United States, Journal of the American Medical Association 289, 179-86.
3. Prince, G. A. (2001). An update on respiratory syncytial virus antiviral agents. Expert Opinion on Investigational Drugs 10, 297-308.
4. Shigeta, S. (2000). Recent progress in antiviral chemotherapy for respiratory syncytial virus infections. Expert Opinion on Investigational Drugs 9, 221-35.
5. Nikitenko, A. A., Raifeld, Y. E. & Wang, T. Z. (2001). The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorganic & Medicinal Chemistry Letters 11, 1041-4.
6. Colman, P. M. & Lawrence, M. C. (2003). The structural biology of type I viral membrane fusion. Nature Reviews Molecular Cell Biology 4, 309-19.
7. Morrison, T. G. (2003). Structure and function of a paramyxovirus fusion protein. Biochimica et Biophysica Acta 1614, 73-84.
8. Feldman, S. A., Audet, S. & Beeler, J. A. (2000). The fusion glycoprotein of human respiratory syncytial virus facilitates virus attachment and infectivity via an interaction with cellular heparan sulfate. Journal of Virology 74, 6442-7.
9. Hallak, L. K., Collins, P. L., Knudson, W. et al. (2000). Iduronic acid-containing glycosaminoglycans on target cells are required for efficient respiratory syncytial virus infection. Virology 271, 264-75.
10. Krusat, T. & Streckert, H. J. (1997). Heparin-dependent attachment of respiratory syncytial virus (RSV) to host cells. Archives of Virology 142, 1247-54.
11. Martinez, I. & Melero, J. A. (2000). Binding of human respiratory syncytial virus to cells: implication of sulfated cell surface proteoglycans. Journal of General Virology 81, 2715-22.
12. Hallak, L. K., Spillmann, D., Collins, P. L. et al. (2000). Glycosaminoglycan sulfation requirements for respiratory syncytial virus infection. Journal of Virology 74, 10508-13.
13. Pastey, M. K., Crowe, J. E., Jr & Graham, B. S. (1999). RhoA interacts with the fusion glycoprotein of respiratory syncytial virus and facilitates virus-induced syncytium formation. Journal of Virology 73, 7262-70.
14. Pastey, M. K., Gower, T. L., Spearman, P. W. et al. (2000). A RhoA-derived peptide inhibits syncytium formation induced by respiratory syncytial virus and parainfluenza virus type 3. Nature Medicine 6, 35-40.
15. Budge, P. J., Lebowitz, J. & Graham, B. S. (2003). Antiviral activity of RhoA-derived peptides against respiratory syncytial virus is dependent on formation of peptide dimers. Antimicrobial Agents and Chemotherapy 47, 3470-7.
16. Budge, P. J., Li, Y., Beeler, J. A. et al. (2004). RhoA-derived peptide dimers share mechanistic properties with other anionic inhibitors of respiratory syncytial virus (RSV), including disruption of viral attachment and dependence on RSV G. Journal of Virology 78, 5015-22.
17. Luscher-Mattli, M. (2000). Polyanions-a lost chance in the fight against HIV and other virus diseases? Antiviral Chemistry and Chemotherapy 11, 249-59.
18. Ikeda, S., Neyts, J., Verma, S. et al. (1994). In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion. Antimicrobial Agents and Chemotherapy 38, 256-9.
19. Richardson, C. D. & Choppin, P. W. (1983). Oligopeptides that specifically inhibit membrane fusion by paramyxoviruses: studies on the site of action. Virology 131, 518-32.
20. Kimura, K., Mori, S., Tomita, K. et al. (2000). Antiviral activity of NMSO3 against respiratory syncytial virus infection in vitro and in vivo. Antiviral Research 47, 41-51.
21. Nikitenko, A. A., Raifeld, Y. E. & Wang, T. Z. (2001). The discovery of RFI-641 as a potent and selective inhibitor of the respiratory syncytial virus. Bioorganic and Medicinal Chemisty Letters 11, 1041-4.
22. Lifson, J. D., Hwang, K. M., Nara, P. L. et al. (1988). Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 241, 712-6.
23. Ohki, K., Kumagai, K., Mitsuda, S. et al. (1993). Characterization of a unique scrambled peptide derived from the CD4 CDR3-related region which shows substantial activity for blocking HIV-1 infection. Vaccine 11, 682-6.
24. Kumagai, K., Tokunaga, K., Tsutsumi, M. et al. (1993). Increased anti-HIV-1 activity of CD4 CDR3-related synthetic peptides by scrambling and further structural modifications, including D-isomerization and dimerization. FEBS Letters 330, 117-21.
25. Rausch, D. M., Lifson, J. D., Padgett, M. P. et al. (1992). CD4(81-92)-based peptide derivatives. Structural requirements for blockade of HIV infection, blockade of HIV-induced syncytium formation, and virostatic activity in vitro. Biochemical Pharmacology 43, 1785-96.
26. Kwong, P. D., Wyatt, R., Robinson, J. et al. (1998). Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393, 648-59.
27. Weiss, W. J., Murphy, T., Lynch, M. E. et al. (2003). Inhalation efficacy of RFI-641 in an African green monkey model of RSV infection. Journal of Medical Primatology 32, 82-8.
28. Yu, K. L., Zhang, Y., Civiello, R. L. et al. (2003). Fundamental structure-activity relationships associated with a new structural class of respiratory syncytial virus inhibitor. Bioorganic and Medicinal Chemistry Letters 13, 2141-4.
29. Douglas, J. L., Panis, M. L., Ho, E. et al. (2003). Inhibition of respiratory syncytial virus fusion by the small molecule VP-14637 via specific interactions with F protein. Journal of Virology 77, 5054-64.
30. Lalezari, J. P., Henry, K., O'Hearn, M. et al. (2003). Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. New England Journal of Medicine 348, 2175-85.
31. Lazzarin, A., Clotet, B., Cooper, D. et al. (2003). Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. New England Journal of Medicine 348, 2186-95.
32. Liu, J. & Thorp, S. C. (2002). Cell surface heparan sulfate and its roles in assisting viral infections. Medicinal Research Reviews 22, 1-25.
33. Shukla, D. & Spear, P. G. (2001). Herpesviruses and heparan sulfate: an intimate relationship in aid of viral entry. Journal of Clinical Investigation 108, 503-10.
34. Batinic, D. & Robey, F. (1992). The V3 region of the envelope glycoprotein of human immunodeficiency virus type 1 binds sulfated polysaccharides and CD4-derived synthetic peptides. Journal of Biological Chemistry. 267, 6664-71.
35. Meshcheryakova, D., Andreev, S., Tarasova, S. et al. (1993). CD4-derived peptide and sulfated polysaccharides have similar mechanisms of anti-HIV activity based on electrostatic interactions with positively charged gp-120 fragments. Molecular Immunology 30, 993-1001.
36. Moulard, M., Lortat-Jacob, H., Mondor, I. et al. (2000). Selective interactions of polyanions with basic surfaces on human immunodeficiency virus type 1 gp120. Journal of Virology 74, 1948-60.
37. Choe, H., Li, W., Wright, P. L. et al. (2003). Tyrosine sulfation of human antibodies contributes to recognition of the CCR5 binding region of HIV-1 gp120. Cell 114, 161-70.
38. Lambert, D. M., Barney, S., Lambert, A. L. et al. (1996). Peptides from conserved regions of paramyxovirus fusion (F) proteins are potent inhibitors of viral fusion. Proceedings of the National Academy of Sciences, USA 93, 2186-91.